TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Phio Pharmaceuticals ( (PHIO) ) is now available.
On October 31, 2025, Robert Ferrara resigned from Phio Pharmaceuticals‘ Board of Directors, including his roles on the Compensation and Audit Committees, and as Lead Independent Director. His resignation led to the Board reducing its size from six to five members. Concurrently, Phio Pharmaceuticals announced the appointment of David Deming as the new Lead Independent Director. Deming, who joined the Board in February 2025, brings over 30 years of experience in investment banking and asset management, which is expected to be a valuable resource as the company advances its gene silencing technology aimed at eliminating cancer.
The most recent analyst rating on (PHIO) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Phio Pharmaceuticals stock, see the PHIO Stock Forecast page.
Spark’s Take on PHIO Stock
According to Spark, TipRanks’ AI Analyst, PHIO is a Neutral.
Phio Pharmaceuticals is struggling financially, with no revenue and consistent losses, significantly impacting its stock score. The technical indicators show mixed signals, with some short-term momentum but bearish long-term trends. The valuation is speculative due to negative earnings. The recent board appointment is a positive corporate event but has limited impact on overall financial health.
To see Spark’s full report on PHIO stock, click here.
More about Phio Pharmaceuticals
Phio Pharmaceuticals Corp. is a clinical-stage siRNA biopharmaceutical company focused on developing immuno-oncology therapeutics using its proprietary INTASYL® gene silencing technology. The company’s lead clinical program, PH-762, targets the PD-1 gene to treat various skin cancers, including cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma.
Average Trading Volume: 127,328
Technical Sentiment Signal: Strong Sell
Current Market Cap: $11.8M
Learn more about PHIO stock on TipRanks’ Stock Analysis page.